Details of the Drug

General Information of Drug (ID: DMCTRLN)

Drug Name
OT-101
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2/3 [1]
Merkel cell carcinoma 2C34 Phase 2/3 [1]
Pancreatic cancer 2C10 Phase 2/3 [2]
Recurrent glioblastoma 2A00.00 Phase 2/3 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Drug Type
Antisense oligonucleotide
Cross-matching ID
TTD ID
DO5H6K
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF beta-2 messenger RNA (TGFB2 mRNA) TTI0KH6 TGFB2_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TGF beta-2 messenger RNA (TGFB2 mRNA) DTT TGFB2 1.51E-17 -0.53 -0.77
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of Oncotelic.